Table 1 Characteristics of the included studies
Study | Country/Year | Number of doses | Total number of patients (Number of patients with serologic response data) | Number of control group (Number of controls with serologic response data) | Underlying disease | Age | Gender (%female) | Type of vaccine received | Time to serologic response evaluation post vaccination | Antibody detection method; criteria for determining seropositivity (if avaliable) |
|---|---|---|---|---|---|---|---|---|---|---|
Agnieszka Matkowska-Kocjan [23] | Poland/2021 | 2 | 65 (57) Allo-HSCT | No | ALL, CML, AML, AA, MDS, HL, others | 21 (18–31) | 40.0% | BNT162b2 | 14–21 days | Anti-SARS-CoV-2 QuantiVac ELISA IgG test (Euroimmun/PerkinElmer subsidiary, Waltham, MA, USA); ≥ 35.2 BAU/mL |
Alexis Maillard [45] | France/2022 | 2 | 687 (687) Allo-HSCT | No | myeloid malignancies, lymphoid malignancies, nonmalignant disease | 59 (46–66) | 41.0% | BNT162b2; mRNA-1273 | 33 days (27–52) | 1. Abbott SARS-CoV-2 IgG II Quant-test (Abbott S IgG); ≥ 50AU/ml 2. Roche Elecsys anti-SARS-CoV-2 S (Roche S tAb); ≥ 0.8U/ml |
3 | 181 (181) Allo-HSCT | 60.5 (49.5–66.9) | 39.4% | Not reported | 3. DiaSorin Liaison SARS-CoV-2 TrimericS IgG (DiaSorin TriS IgG) ≥ 13AU/ml 4. Siemens SARS-CoV-2 IgG (Siemens sCOVG); ≥ 1.0 U/ml 5. Wantai SARS-CoV-2 IgG ELISA (Wantai S IgG) ≥ 0.75 AU/ml | |||||
Amandine Le Bourgeois [46] | France/2021 | 2 | 117 (117) Allo-HSCT | No | AML, MDS, MF, MDS/MF, CML, BPDCN, NHL, HL, ALL, MM, NNAA, porphyria | 57 (20–75) | 40.0% | BNT162b2 | 35 (18–77) days | Elecsys anti–SARS-CoV-2-S (Roche Elecsys, Rotkreuz, Switzerland); ≥ 0.8 U/mL |
Amandine Le Bourgeois-2 [44] | France/2021 | 3 | 80 (80) Allo-HSCT | 25 (25) Healthy controls | myeloid, lymphoid, others | 57 (20–75) | 43.8% | BNT162b2 | 94.5 (55–220) days | Elecsys anti–SARS-CoV-2-S (Roche Elecsys, Rotkreuz, Switzerland); ≥ 0.8 U/mL |
Anne-Claire Mamez [43] | Switzerland/2021 | 2 | 63 (63) Allo-HSCT | No | Acute leukemia, MDS/MPS, lymphoid diseases, hemoglobinopathie | 54 (18–78) | 38.0% | BNT162b2; mRNA-1273 | 38 (13–98) days | Semi-quantitative Elecsys ® Anti-SARSCoV-2 immunoassay (Roche); ≥ 0.8 U/mL |
Binod Dhakal [47] | US/2021 | 1, 2 | 71 (71) Allo-HSCT; 45 (45) Auto-HSCT; 14 (14) CAR T | No | lymphoma, myeloma, some were not reported | 25–77 | not reported | BNT162b2; mRNA-1273; Ad26.COV2.S | ≥ 2 weeks | Enzyme immunoassay testing antibodies to the S1 domain of the SARS-CoV-2 spike protein (EUROIMMUN) |
Caroline Pabst [24] | Germany/2022 | 1, 2 | 167 (167) Allo-HSCT | 134 (134) Healthy controls | AML, MDS, MPN, AA, ALL, MM, lymphoma | 60 (19–79) | 38.9% | BNT162b2; mRNA-1273; ChAdOx1 | Not reported | Surrogate virus neutralization test (Medac, Wedel, Germany) |
José Luis Piñana[25] | Spain/2021 | 2 | 311 (311) Allo-HSCT 86 (86) Auto-HSCT | No | AML, MDS, NHL, MM, CLL, HD, MPN, ALL, others | Allo: 56.7 (18–80) Auto: 64.6 (19–78) | Allo: 40.0% Auto: 43.0% | mRNA-1273; BNT162b2; ChAdOx1; Ad26.COV2.S | 3–6 weeks | 1. Abbott Architect SARS-CoV-2 IgG Quant II chemiluminescent microparticle immunoassay (Abbott, Sligo, Ireland) 2. Liaison SARS-CoV-2 S1/S2 IgG chemiluminescent assay (DiaSorin S.p.A., Saluggia, Italy) 3. Euroimmun SARS-CoV-2 IgG ELISA (Euroimmun, Lübeck, Germany) 4. MAGLUMI 2019-nCoV IgG chemiluminescent assay (SNIBE—Shenzhen New Industries Biomedical Engineering Co., Ltd., Shenzhen, China) 5. COVID-19 ELISA IgG (Vircell Spain S.L.U., Granada, Spain) |
Kalpana Parvathaneni [41] | US/2021 | 2 | 12 (12) CAR T | 8 (8) Healthy controls | B-ALL, DLBCL, NHL, MCL, CLL | 53 (16–74) | 25.0% | BNT162b2; mRNA-1273 | Up to 28 days | Not reported |
Katie Healy [35] | Sweden/2021 | 2 | 74 (69) Allo-HSCT/CAR T | 82 (82) Healthy controls | Not reported | 60 (51–67) | 45.0% | BNT162b2 | 14 days | Elecsys® Anti-SARS-CoV-2 S assay (Roche Diagnostics); ≥ 0.80 U/mL |
Lorenzo Canti [26] | Belgium/2021 | 1 | 40 (37) Allo-HSCT | 40 (40) Healthy controls | Not reported | 60 (26–76) | 52.5% | BNT162b2 | 21 days | WANTAI SARS-Cov-2 Ab ELISA (Beijing Wantai Biological Pharmacy Enterprise, Beijing, China) |
2 | 40 (37) Allo-HSCT | 40 (40) Healthy controls | 28 days | |||||||
Lorenzo Canti-2 [39] | Belgium/2022 | 3 | 38 (38) Allo-HSCT | No | Not reported | 60 (26–76) | 50.0% | BNT162b2 | 28 days | WANTAI SARS-Cov-2 Ab ELISA (Beijing Wantai Biological Pharmacy Enterprise, Beijing, China) |
Martina Chiarucci [27] | Italy/2021 | 2 | 12 (12) Allo-HSCT; 38 (38) Auto-HSCT | 45 (0) Healthy controls | Auto-HSCT: MM, NHL, HL; Allo-HSCT: AML, ALL, MDS | 61 (21–72) | 44.0% | BNT162b2 | 30 days | Anti-SARSCoV-2 IgG CLIA (LIAISON ® SARS-CoV-2 TrimericS IgG assay, Diasorin, Saluggia, Italy) |
Marika Watanabe [28] | Japan/2022 | 2 | 25 (25) Allo-HSCT | 19 (19) Healthy controls | AML, ALL, malignant lymphoma, others | 55 (23–71) | 44.0% | BNT162b2 | 14 days (+ / − 7 days) | QuaResearch COVID-19 Human IgM IgG ELISA kit (Spike Protein-S1) (Cellspect, Inc., RCOEL961S1, Iwate, Japan); > 0.26 (optical density value) |
Maciej Majcherek [29] | Poland/2022 | 2 | 64 (63) Allo-HSCT; 29 (26) Auto-HSCT; | No | AML, MM, NHL, HL, MDS, ALL | Allo-HSCT: 52 (20–68); Auto-HSCT: 58 (26–69) | Allo-HSCT: 45.0%; Auto-HSCT: 48.0% | BNT162b2 | 2–4 weeks | Chemiluminescent microparticle immunoassay (CMIA) “Alinity I” (Abbott Diagnostics) |
Monika Lindemann [30] | Germany/2021 | 2 | 117 (117) Allo-HSCT | 35 (35) Healthy controls | Acute leukemia, MDS, MPN, lymphoma, others | 59 (21–77) | 52.1% | BNT162b2; mRNA-1273; ChAdOx1 | 31 (11–137) days | CE marked Anti-SARS-CoV-2 IgG semi-quantitative ELISA (Euroimmun, Lübeck, Germany); |
Muhammad Bilal Abid [48] | US/2022 | 3 | 26 (26) Allo-HSCT; 30 (30) Auto-HSCT; 10 (10) CAR T | No | Lymphoma, myeloma | 31–81 | 32.0% | BNT162b2; mRNA-1273; | At least 14 days | AdviseDx SARS-CoV-2 IgG II assay; > 50.0 AU/mL |
Noga Shem-Tov [31] | Israel/2021 | 2 | 176 (152) Allo-HSCT | 272 (272) Healthy controls | AML, MDS, MPD, ALL, NHL, HL, CLL, AA | 58.4 ± 14.0 (mean ± SD) | 36.8% | BNT162b2 | 2–4 weeks | Mount Sinai Hospital Clinical Laboratory SARS-CoV-2 IgG Antibody Test; |
Patrice Chevallier [32] | France/2021 | 1 | 112 (112) Allo-HSCT | 26 (26) Healthy controls | AML, MDS, MF, MDS/MF, CML, BPDCN, NHL, HL, ALL, MM, AA, porphyria | 57 (20–75) | 40.2% | BNT162b2 | 16–35 days | Roche Elecsys; ≥ 0.8 U/ml |
Peter Bergman [49] | Sweden/2021 | 2 | 87 (70) Allo-HSCT; 3 (2) CAR T | 90 (78) Healthy controls | not reported | 74% < 65 | 47.0% | BNT162b2 | 14 days | Elecsys ® AntiSARS-CoV-2 S (Roche Diagnostics); ≥ 0.8 U/ml |
Rabah Redjoul [37] | France/2021 | 2 | 88 (88) Allo-HSCT | No | Myeloid malignancy, lymphoid malignancy and nonmalignant | 26–77 | 46.6% | BNT162b2 | 28 (IQR 26–31) days | IgG II Quant Assay (Abbot Laboratories, Wiesbaden, Germany); |
Ron Ram [36] | Israel/2021 | 2 | 66 (57) Allo-HSCT; 14 (14) CAR T | No | AML, MDS, ALL, DLBCL, other lymphoma, MPN, others | 65 (23–83) | 45.0% | BNT162b2 | 7–14 days | Elecsys Anti-SARS-CoV-2 S assay on the Cobas e411 (Roche Diagnostics, Basel, Switzerland); ≥ 0.80 U/mL |
Roni Tamari [33] | US/2021 | 1 | 149 (149) Allo-HSCT; 61 (61) Auto-HSCT; 7 (7) CAR T | 69 (54) Healthy controls | Acute leukemia, MDS/MPN, chronic leukemia, MM and amyloid, lymphoma, AA, SA, BPDCN | 66.4 (25.8–84.1) | 40.6% | BNT162b2; mRNA-1273 | 3 months | AdviseDx SARS-CoV-2 IgG II assay; > 50.0 AU/mL |
Sandra Easdale [34] | UK/2021 | 1 | 55 (55) Allo-HSCT | No | ALL, AML, AA, MDS, NHL, HL, MF | 50 (18–73) | 38.2% | BNT162b2; ChAdOx1 | 14–84 days | Ortho Clinical Diagnostic Anti-SARS-CoV-2 IgG antibody methods (Ortho Clinical Diagnostics, USA); |
Saurabh Dahiya [40] | US/2022 | 2 | 14 (14) CAR T | 4 (4) Healthy controls | LBCL, MCL, FL | 50.5 (24–87) | 33.0% | BNT162b2; mRNA-1273 | 4 weeks | |
3 | 6 (6) CAR T | No | Not reported | Not reported | ~ 1 month | |||||
Thomas A. Fox [42] | UK/2021 | 2 | 11 (11) CAR T | No | B-ALL, NHL, CLL, WM | Not reported | Not reported | BNT162b2; ChAdOx1 | 1 month | Quantitative double-antigen sandwich immunoassays (Roche, Basel, Switzerland); > 0.4 µ/ml |
Thomas Gastinne [38] | France/2021 | 1, 2 | 23 (23) CAR T | 25 (25) Healthy controls | Lymphoma, ALL | 62 (21–79) | 39.1% | BNT162b2 | 29 (16–32) days after 1st dose and 52 (21–99) days after 2nd dose | Several serological techniques but mainly the Roche Elecsys assay |